Literature DB >> 27780968

Mantle cell lymphoma initial therapy with abbreviated R-CHOP followed by 90Y-ibritumomab tiuxetan: 10-year follow-up of the phase 2 ECOG-ACRIN study E1499.

M R Smith1, F Hong2, H Li2, L I Gordon3, R D Gascoyne4, E M Paietta5, R H Advani6, A Forero-Torres7, S J Horning6, B S Kahl8.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27780968      PMCID： PMC5288271          DOI： 10.1038/leu.2016.305

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  15 in total

1.  Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur.

Authors:  Christian H Geisler; Arne Kolstad; Anna Laurell; Mats Jerkeman; Riikka Räty; Niels S Andersen; Lone B Pedersen; Mikael Eriksson; Marie Nordström; Eva Kimby; Hans Bentzen; Outi Kuittinen; Grete F Lauritzsen; Herman Nilsson-Ehle; Elisabeth Ralfkiaer; Mats Ehinger; Christer Sundström; Jan Delabie; Marja-Liisa Karjalainen-Lindsberg; Peter Brown; Erkki Elonen
Journal:  Br J Haematol       Date:  2012-05-29       Impact factor: 6.998

2.  Confirmation of the mantle-cell lymphoma International Prognostic Index in randomized trials of the European Mantle-Cell Lymphoma Network.

Authors:  Eva Hoster; Wolfram Klapper; Olivier Hermine; Hanneke C Kluin-Nelemans; Jan Walewski; Achiel van Hoof; Marek Trneny; Christian H Geisler; Francesco Di Raimondo; Michal Szymczyk; Stephan Stilgenbauer; Catherine Thieblemont; Michael Hallek; Roswitha Forstpointner; Christiane Pott; Vincent Ribrag; Jeanette Doorduijn; Wolfgang Hiddemann; Martin H Dreyling; Michael Unterhalt
Journal:  J Clin Oncol       Date:  2014-03-31       Impact factor: 44.544

Review 3.  Recommendations for Clinical Trial Development in Mantle Cell Lymphoma.

Authors:  Stephen E Spurgeon; Brian G Till; Peter Martin; Andre H Goy; Martin P Dreyling; Ajay K Gopal; Michael LeBlanc; John P Leonard; Jonathan W Friedberg; Lawrence Baizer; Richard F Little; Brad S Kahl; Mitchell R Smith
Journal:  J Natl Cancer Inst       Date:  2016-12-31       Impact factor: 13.506

4.  Treatment of older patients with mantle-cell lymphoma.

Authors:  H C Kluin-Nelemans; E Hoster; O Hermine; J Walewski; M Trneny; C H Geisler; S Stilgenbauer; C Thieblemont; U Vehling-Kaiser; J K Doorduijn; B Coiffier; R Forstpointner; H Tilly; L Kanz; P Feugier; M Szymczyk; M Hallek; S Kremers; G Lepeu; L Sanhes; J M Zijlstra; R Bouabdallah; P J Lugtenburg; M Macro; M Pfreundschuh; V Procházka; F Di Raimondo; V Ribrag; M Uppenkamp; M André; W Klapper; W Hiddemann; M Unterhalt; M H Dreyling
Journal:  N Engl J Med       Date:  2012-08-09       Impact factor: 91.245

5.  Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma.

Authors:  Tadeusz Robak; Huiqiang Huang; Jie Jin; Jun Zhu; Ting Liu; Olga Samoilova; Halyna Pylypenko; Gregor Verhoef; Noppadol Siritanaratkul; Evgenii Osmanov; Julia Alexeeva; Juliana Pereira; Johannes Drach; Jiri Mayer; Xiaonan Hong; Rumiko Okamoto; Lixia Pei; Brendan Rooney; Helgi van de Velde; Franco Cavalli
Journal:  N Engl J Med       Date:  2015-03-05       Impact factor: 91.245

6.  Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival.

Authors:  Orion M Howard; John G Gribben; Donna S Neuberg; Michael Grossbard; Christina Poor; Milos J Janicek; Margaret A Shipp
Journal:  J Clin Oncol       Date:  2002-03-01       Impact factor: 44.544

7.  Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center.

Authors:  Dai Chihara; Chan Y Cheah; Jason R Westin; Luis E Fayad; Maria A Rodriguez; Fredrick B Hagemeister; Barbara Pro; Peter McLaughlin; Anas Younes; Felipe Samaniego; Andre Goy; Fernando Cabanillas; Hagop Kantarjian; Larry W Kwak; Michael L Wang; Jorge E Romaguera
Journal:  Br J Haematol       Date:  2015-12-09       Impact factor: 6.998

8.  First-line treatment with rituximab-hyperCVAD alternating with rituximab-methotrexate-cytarabine and followed by consolidation with 90Y-ibritumomab-tiuxetan in patients with mantle cell lymphoma. Results of a multicenter, phase 2 pilot trial from the GELTAMO group.

Authors:  Reyes Arranz; Ana García-Noblejas; Carlos Grande; Jimena Cannata-Ortiz; José J Sánchez; José-Antonio García-Marco; Concepción Aláez; Javier Pérez-Calvo; Pilar Martínez-Sánchez; Blanca Sánchez-González; Miguel-Angel Canales; Eulogio Conde; Alejandro Martín; Eva Arranz; María-José Terol; Antonio Salar; Dolores Caballero
Journal:  Haematologica       Date:  2013-06-10       Impact factor: 9.941

9.  Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909.

Authors:  Lloyd E Damon; Jeffrey L Johnson; Donna Niedzwiecki; Bruce D Cheson; David D Hurd; Nancy L Bartlett; Ann S Lacasce; Kristie A Blum; John C Byrd; Michael Kelly; Wendy Stock; Charles A Linker; George P Canellos
Journal:  J Clin Oncol       Date:  2009-11-16       Impact factor: 44.544

10.  Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.

Authors:  Michael L Wang; Simon Rule; Peter Martin; Andre Goy; Rebecca Auer; Brad S Kahl; Wojciech Jurczak; Ranjana H Advani; Jorge E Romaguera; Michael E Williams; Jacqueline C Barrientos; Ewa Chmielowska; John Radford; Stephan Stilgenbauer; Martin Dreyling; Wieslaw Wiktor Jedrzejczak; Peter Johnson; Stephen E Spurgeon; Lei Li; Liang Zhang; Kate Newberry; Zhishuo Ou; Nancy Cheng; Bingliang Fang; Jesse McGreivy; Fong Clow; Joseph J Buggy; Betty Y Chang; Darrin M Beaupre; Lori A Kunkel; Kristie A Blum
Journal:  N Engl J Med       Date:  2013-06-19       Impact factor: 91.245
View more
  4 in total

Review 1.  Toward a Risk-Tailored Therapeutic Policy in Mantle Cell Lymphoma.

Authors:  Adalgisa Condoluci; Davide Rossi; Emanuele Zucca; Franco Cavalli
Journal:  Curr Oncol Rep       Date:  2018-08-22       Impact factor: 5.075

Review 2.  Frontline Treatment for Older Patients with Mantle Cell Lymphoma.

Authors:  Haige Ye; Aakash Desai; Dongfeng Zeng; Jorge Romaguera; Michael L Wang
Journal:  Oncologist       Date:  2018-06-12

3.  Radioimmunotherapy for mantle cell lymphoma: 5-year follow-up of 90 patients from the international RIT registry.

Authors:  Karin Hohloch; Christine Windemuth-Kieselbach; Pier Luigi Zinzani; Roberto Cacchione; Wojciech Jurczak; C Suh; Lorenz Trümper; Christian W Scholz
Journal:  Ann Hematol       Date:  2020-03-03       Impact factor: 3.673

Review 4.  Paramount therapy for young and fit patients with mantle cell lymphoma: strategies for front-line therapy.

Authors:  Haige Ye; Aakash Desai; Shengjian Huang; Dayoung Jung; Richard Champlin; Dongfeng Zeng; Fangfang Yan; Krystle Nomie; Jorge Romaguera; Makhdum Ahmed; Michael L Wang
Journal:  J Exp Clin Cancer Res       Date:  2018-07-13
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.